Cardium Therapeutics Inc Stock Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Financials (USD)
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K |
---|---|---|---|---|---|
Net income 2019 | - | Net income 2020 | - | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M | Net Debt 2020 | 874K | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Lois Chandler
COO | Chief Operating Officer | - | 10-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 03-12-21 | |
James Grainer
CHM | Chairman | 69 | 20-05-21 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 20-05-21 |
1st Jan change | Capi. | |
---|---|---|
+2.24% | 42.75B | |
+47.70% | 41.61B | |
+11.98% | 41.34B | |
-8.83% | 26.59B | |
+6.49% | 25.49B | |
-22.92% | 18.12B | |
+30.28% | 12.24B | |
-2.23% | 11.76B | |
+9.19% | 11B |